Children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of 21q have been identified previously as a new cytogenetic subgroup 1,2 with a frequency of 1.5% in a large series of patients. 3 The amplification is most often detected as multiple copies of RUNX1 (AML1) signals, which are seen as clusters during interphase fluorescence in situ hybridization (FISH) analysis using ETV6/RUNX1 probes. The common region of amplification (CRA) spanning 6.5-6.6 Mb was recently reported using high-resolution array-CGH of chromosome 21 and the whole genome changes were characterized using BAC array-CGH with a resolution of 1 Mb. 4 We have used a tiling resolution 33 K BAC array and interphase FISH to investigate seven children with ALL with intrachromosomal amplification of 21q to characterize in detail the amplified region, as well as any additional genomic imbalances. We have also tested a possible mechanism by which this amplification could occur (see Materials and methods section in Supplementary Information).
Seven children with ALL, treated at Karolinska University Hospital 1997-2006, were diagnosed with amplification of 21q by FISH and included in the study. The project was approved by the Research Ethics Committee at Karolinska Institutet. The patients shared the characteristic features reported for other ALL patients with 21q amplification, as older age of onset (7-15 years old) and low white blood cell count at diagnosis (Supplementary Table 1 ). Patients with 21q amplification are currently treated as high risk in at least one protocol (UKALL 2003), but not in others, for example the ongoing Nordic protocol NOPHO ALL-2000. A recently published report assessing the relationship between intrachromosomal amplification of 21q and event-free survival in 28 ALL patients established clear evidence for adverse prognosis in the specific group of patients with a 5-year event-free survival of 29% when the patients were treated according to the UK MRC ALL97 protocol. 5 In the present study, patient no. 1 was treated as standard risk (SR), patient no. 2 as high risk (HR) owing to bulky lymphomatous organ involvement at diagnosis, and the remaining patients were stratified into the intermediate-risk (IR) group according to the NOPHO ALL-92 and NOPHO ALL-2000 protocols. In spite of a median observation time of 58 months (range, 15-119 months), only one of the IR patients has relapsed. This emphasizes the need to gather knowledge about this group of patients to provide an accurate risk assessment at diagnosis.
Genetic analyses including karyotyping by G-banding, SKY and interphase FISH for BCR/ABL, ETV6/RUNX1, PBX1/TCF3 and MLL rearrangements, as well as 9p21 deletion were performed as part of the routine investigation. Only two patients had abnormalities detected by G-banding (nos. 3 and 5). Amplification of 21q was suspected by interphase FISH analysis on diagnostic bone marrow smears using the ETV6/RUNX1 probe. The number of gene copies varied between 4 and 15 in different samples and between 3-4 and 12-15 in different cells from the same patient. The results of array-CGH are shown in Table 1 . Overall, we performed array-CGH on nine samples: seven diagnostic and two relapse samples (from case no. 3). In case no. 1, no unbalanced changes were detected on Table 1 Summary of cytogenetic findings and array-CGH results
Case
Karyotype after SKY and FISH Chromosome 21 findings Array-CGH findings
46,XY,t(1;12)(q41;p13),i(9)(10),dup(21q)/ 46,XY,t(8;12)(q24;p13),i(9)(10),del(16)(q11),dup(21q)
,XY,der(3),À7,der(7)t(7;18) arr cgh 21q21.1q22.11(RP11-550D18-RP11-781A17) Â 3-4 arr cgh 7p22.3q32.3(CTD-2245C5-RP11-193I17) Â 1 3 (R2) (p?22;q?21),der(9)t(7;9)(?;p1?), arr cgh 21q22.11q22.
arr cgh 7q34(RP11-786A19-RP11-114L10) Â 1 arr cgh 21q22. , which is larger than the recently reported CRA of 6.5-6.6 Mb in a series of 10 patients. 4 It also overlaps with the two regions found to be amplified in patients with AML (25-30 Mb and 38.7 and 39.1 Mb). 6 In three out of six patients, array-CGH allowed identification of a 0.9-4.2 Mb deletion (0.6 Mb common region of deletion (CRD)) of the most telomeric part of 21q, distal to the amplified region. This finding also confirms previous data, but the size of the CRD is smaller in our study. Interphase FISH using a 21q subtelomere probe confirmed a deletion of 21qter in case nos. 2 and 6, as well as different degrees of amplification in case nos. 1, 5 and 7. Interphase and metaphase FISH analyses using BAC clones RP11-114H1 at 21q22.2, RP11-539O13 at 21q21.3 and RP11-53E17 at 21q23 confirmed the array-CGH findings with increased amplification toward the telomere and deletion of 21qter. Additional genomic imbalances were identified by array-CGH and allowed us to revise the karyotypes (Table 1) . A large deletion of 7q of varying size was observed in three diagnostic samples (nos. 2, 4, and 7) as well as in both relapses from case no. 3 ( Table 1 ). The size of the deletion varied significantly between the samples, from 33.9 to 132.5 Mb, with a CRD of 22.4 Mb. Recurrent deletions of 7q34 (0.2 Mb) and 14q32.33 (1.0 Mb) were observed within regions of known polymorphisms (Database of Genomic variants, http://projects. tcag.ca/variation/). This finding most likely reflects somatic immunoglobulin rearrangements clonotypic for the leukemic blasts 7 or intercellular polymorphism. Case no. 3 was the only patient in the study who relapsed, and therefore, both diagnostic and relapse samples were analyzed (nos. 3, 3a and 3b). The array-CGH plot from diagnostic case no. 3 had a high background noise, and we were unfortunately not able to repeat the array-CGH experiment owing to lack of diagnostic material. No telomeric deletion on 21q was observed on array-CGH plot, whereas the two relapse samples from the same patient showed a terminal deletion. Interphase FISH using a subtelomere probe from 21q was applied on cells from the diagnostic chromosome suspension and confirmed a deletion of the terminal part of 21, which was not picked up by the array. Interphase and metaphase FISH analyses using BAC clones mentioned above verified the stepwise character of amplification in case no. 3. These findings suggest a similar character of amplification in the diagnostic and relapse samples from case no. 3. The karyotype of the original malignant clones differed from the clone at relapse ( Table 1 ). The relapse samples were similar by Gbanding and SKY and almost identical by array-CGH, but more and larger deletions were found in the sample from the second relapse. Array-CGH has made it possible to revise and specify the cytogenetic results in the karyotype of both the diagnostic and relapse samples (Table 1) . Chromosome 9 abnormalities, although not identical, were present in all samples: an isochromosome 9q was identified at diagnosis, whereas frank deletion of 9p was found at relapse. The deletion of 7q increased in size along with the progression of the disease. A few additional imbalances were identified at second relapse compared to the first, which may be indicative of clonal evolution (Table 1 ). In the diagnostic sample, the array-CGH plot of chromosome 16 indicated an interstitial deletion of 16q. Interphase FISH confirmed an interstitial deletion of 16q corresponding to the clone bearing t(8;12) in 40% of the malignant cells. Thus, in case no. 3, who suffered a relapse 4 years after diagnosis, the only recurrent genetic event in the diagnostic and relapse clones was the intrachromosomal amplification of 21q. This suggests that 21q amplification is a primary event, important for the establishment and progression of disease.
The inter-individual difference in the size of the amplified as well as the deleted segments reflects the nature of intrachromosomal amplification of 21q, including high variability and instability, and indicates telomere dysfunction. Similar low-copy gene amplification has previously been found in cancer cells as a result of breakage/fusion/bridge (BFB) cycles that are initiated by the loss of the telomere and fusion of sister chromatids. 8 The fused, dicentric chromosome will break during anaphase, when the two centromeres are pulled apart. The BFB cycles are then continued during the following cell cycles and terminate when the unstable chromosome acquires a new telomere. We performed Giemsa staining of bone marrow smears from diagnosis and relapse when possible to explore BFB cycles as a possible mechanism of formation. Structures looking like anaphase bridges could be found in case nos. 4 and 3a but not in case nos. 5 and 6. To show that these bridges involved chromosome 21, interphase FISH with whole chromosome painting probes from chromosomes 21 and 22 was performed, and anaphase bridges formed by fused chromosomes 21 were observed (Figure 2 ). The fact that anaphase bridges were not found in all patients may be explained by the acquirement of a new telomere stabilizing the rearrangement, and therefore no ongoing BFB cycles.
In summary, the detailed characterization of the 21q amplification in six children with ALL suggested BFB cycles as a possible mechanism of amplification. Tiling array-CGH revealed a heterogeneous character of the amplification with a stepwise pattern of the amplification in all patients and a telomeric deletion in five out of six cases. Our follow-up data suggest a better prognosis for these patients than previously reported; however, before any larger follow-up studies have been published, the prognostic impact of 21q amplification remains uncertain.
